HOOKIPA Pharma Inc (HOOK) Actualités

Form 4 - Statement of changes in beneficial ownership of securities

HOOKIPA Pharma Announces Leadership Changes to Intensify Focus on HB-200

Director Dr. Malte Peters named Chief Executive Officer and Director Terry Coelho named Executive Vice...

Form 8-K - Current report

HOOKIPA Pharma Announces Effective Date of 1-for-10 Reverse Stock Split

NEW YORK and VIENNA, July 08, 2024 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, “HOOKIPA”), a...

HOOKIPA Pharma Announces First Person Dosed in Phase 1b Clinical Trial of HB-500 for the Treatment of HIV

Novel arenaviral therapeutic vaccine, developed in collaboration with Gilead Sciences, Inc. (Gilead), to be...

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 8-K - Current report

Form 8-K - Current report

HOOKIPA Pharma Announces Updated Phase 2 Clinical Data at the American Society of Clinical Oncology 2024 Annual Meeting

Encouraging clinical activity with observed deepening of responses in 35 evaluable first line head and neck...

HOOKIPA Pharma to Host Investor Call on HB-200 Data Presented at American Society of Clinical Oncology 2024 Annual Meeting

Company will present promising preliminary progression-free survival and overall survival data for patients...

Form 8-K - Current report

HOOKIPA Pharma Announces Positive Clinical Data to be Presented at the American Society for Clinical Oncology 2024 Annual Meeting

HOOKIPA to present an oral abstract at the American Society for Clinical Oncology (ASCO) 2024 Annual Meeting on...